Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

On Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.

Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis.

Also Read: Analyst Sees Keros Therapeutics As Next Acceleron, the Set For Major Biotech Growth

The FDA has granted Fast Track designation for elritercept for very low-, low- and intermediate-risk MDS.

Myelodysplastic syndromes and myelofibrosis are characterized by inadequate blood cell production, often leading to severe anemia.

Elritercept targets activin A and B proteins, which are believed to be crucial in anemia-associated diseases.

In early clinical studies, elritercept has shown promising clinical activity ...

Full story available on Benzinga.com